#CureSMA2021 – Evrysdi Linked to Improved Motor Function in 2 Trials

#CureSMA2021 – Evrysdi Linked to Improved Motor Function in 2 Trials

297506

#CureSMA2021 – Evrysdi Linked to Improved Motor Function in 2 Trials

Evrysdi (risdiplam) continues to be linked to motor function improvements in a broad range of people with spinal muscular atrophy (SMA), according to recent data from two ongoing Phase 2 clinical trials. These data were presented at the 2021 Virtual SMA Research & Clinical Care Meeting. Presymptomatic babies treated with Evrysdi for at least a year reached many of the same motor skill milestones as healthy children, the data show, while people between the ages…

You must be logged in to read/download the full post.